

Patient data (please fill out clearly in block letters)



Family name																			
First name										Day		Month		Year					
ID. No.										Age									
										<input type="radio"/> male <input type="radio"/> female									



Center for Human Genetics

member of



Diagnosticum

laboratory medicine • microbiology • pathology
human genetics

Request form

personal genomics services DNA analyses

bio.logis Center for Human Genetics

Prof. Dr. med. D. Steinberger · Human Geneticist
Altenhöferallee 3 · 60438 Frankfurt am Main · Germany
T +49 69-530 84 37-0 · T +49 69-530 84 37-11
www.biologis.com · info@biologis.com

Physician

Sample type

☐ Blood/EDTA tube No. of tubes sent Sampling date: Time:

Analyses

Genetic variants relevant for...

- | | | |
|---|--|---|
| <ul style="list-style-type: none"> <input type="radio"/> PGS.lactose
...lactose tolerance in adults <input type="radio"/> PGS.celiac
...gluten tolerance <input type="radio"/> PGS.nutrition
...tolerance and metabolism of food, such as
gluten, lactose, fructose, folic acid and iron <input type="radio"/> PGS.thrombosis
...risk of thrombosis associated with oral
contraception, pregnancy, miscarriage,
long-distance flights <input type="radio"/> PGS.prevention
...preventive care against thrombosis,
lactose intolerance, iron storage disease | <ul style="list-style-type: none"> <input type="radio"/> PGS.clopidogrel
...efficacy and safety of clopidogrel <input type="radio"/> PGS.statins
...efficacy and safety of statins <input type="radio"/> PGS.tamoxifen
...efficacy and safety of tamoxifen <input type="radio"/> PGS.thiopurine
...safety of thiopurine analogs <input type="radio"/> PGS.5-FU
...safety of 5-FU containing drugs <input type="radio"/> PGS.pharma
...metabolism, efficacy and safety of medication <input type="radio"/> PGS.androgen receptor
...sensitivity to testosterone | <ul style="list-style-type: none"> <input type="radio"/> PGS.carrier
...family planning and children. Additional
variants relevant for descendants of the
Ashkenazi Jews <input type="radio"/> PGS.complete
... screening package consisting of more than
100 genetic variants of benefit categories
pharmacogenetics, prevention, carrier <input type="radio"/> Expertise for individual clinical issues
Please specify indication/clinical data
on the back of this form. |
|---|--|---|

Payment

Please note, that diagnostics will not start until payment has been received.

Informing and Informed Consent

You have decided to use bio.logis' *personal genomics services* (PGS). Genetic analyses will be performed on either saliva or blood samples.

PGS informs you about common genetic predispositions.

This knowledge enables you to take appropriate measures to reduce health-related problems. Depending on the PGS.box you have ordered, the analysis also informs about genetic variants influencing efficacy and tolerance of drugs.

Provided several family members have been tested and have access to each others' test results, unexpected results can emerge such as questionable paternity or other unknown relationships within the family.

All tests are anonymous, third parties do not have access to your data.

Additional information on PGS is provided on the bio.logis PGS portal or in the flyer provided with the PGS.box.

You can revoke your informed consent at any time. You need not give the reason and you do not encounter personal disadvantages.

Written revocation should be sent to bio.logis. Should you need support contact bio.logis at: +49 69-59 79 70 30-0

In case data on your analysis are available at the time of your revocation, these will be immediately destroyed and your online access will be shut down. Do not activate your online access in case you are not interested in the results of your genetic analysis.

bio.logis codes your sample before processing. Therefore you need to provide your bar code number and not your name in case of revocation.

All test results are treated with standard medical confidentiality. It is my responsibility alone to inform other family members of genetic risks they may have, and that results will only be released to my physician(s).

The results of the test may be saved for a longer time than the legally required ten years. This can be important for future family analyses.

Once the test has been performed I will leave the remaining sample if any to the laboratory which has performed the analysis (this is according to German law § 950 BGB). I agree to the possible use of my (or my child's) anonymised sample for scientific purposes.

(delete where not applicable)

I have been informed about my right to rescind this agreement. I have read this informed consent and understand it. I have read and received a copy of this consent form. I confirm that I agree with the planned genetic analysis as outlined above.

place / date

name / first name: patient / legal guardian (please print)

signature

Physician:

I have explained to the proband who signed above the purpose of this genetic testing, the procedures required and the possible risks and benefits to the best of my ability.

Professional obtaining consent signature

Date



Analyses

PGS.lactose

- Lactose intolerance /lactase persistence (*LCT*)

PGS.celiac

- Celiac disease (*HLA*)

PGS.nutrition

- Alcohol metabolism (*ADH1B, ALDH2*)
- Antioxidants, detoxication, oxidative stress (*SOD2*)
- Celiac disease (*HLA*)
- Copper storage disease (Wilsons disease) (*ATP7B*)
- Degradation of aromatic and heterocyclic amines, i.a. in cigarette smoke, grilled meat and fish (*NAT2*)
- Disposition for osteoporosis (*COL1A1*)
- Favism, G6PD deficiency (*G6PD*)
- Folic acid metabolism (*SLC19A1, MTHFR*)
- Fructose intolerance, hereditary (*ALDOB*)
- Gilbert’s disease (*UGT1A1*)
- Hemochromatosis (*HFE*)
- Hypercholesterolemia (*APOB*)
- Lactose intolerance /lactase persistence (*LCT*)
- Lipometabolism (*ADRB3*)

PGS.thrombose

- Disposition for thrombophilia (*F2, F5, MTHFR, PAI1*)

PGS.prevention

- Alcohol metabolism (*ADH1B, ALDH2*)
- Alpha-1 antitrypsin deficiency, chronic lung disease (*AAT*)
- Antioxidants, detoxication, oxidative stress (*SOD2*)
- Blood pressure regulation (*AGT, AGTR1*)
- Celiac disease (*HLA*)
- Copper storage disease (Wilsons disease) (*ATP7B*)
- Crohn’s disease (*NOD2*)
- Cystic fibrosis (mucoviscidosis) (*CFTR*)
- Diabetic retinopathy, risk of (*PON1*)
- Disposition for osteoporosis (*COL1A1*)
- Disposition for thrombophilia (*F2, F5, MTHFR, PAI1*)
- Familial Mediterranean fever(*MEFV*)
- Favism, G6PD deficiency (*G6PD*)
- Folic acid metabolism (*SLC19A1, MTHFR*)
- Fructose intolerance, hereditary (*ALDOB*)
- Gilbert’s disease (*UGT1A1*)
- Hemochromatosis (*HFE*)
- Hypercholesterolemia (*APOB*)
- Lactose intolerance /lactase persistence (*LCT*)
- Lipometabolism (*ADRB3*)
- MCAD deficiency (*ACADM*)
- Sickle cell disease (*HBB*)
- Sports performance types (*ACE, ACTN3*)

PGS.clopidogrel

- Metabolism of clopidogrel (*CYP2C19*)

PGS.statins

- Statin treatment, intolerance /effect (*SLCO1B1*)

PGS.tamoxifen

- Tamoxifen, effect of (*CYP2D6*)

PGS.thiopurine

- Thiopurine analogs, toxicity of (*TPMT*)

PGS.5-FU

- 5-fluorouracil (5-FU) toxicity (*DPD*)

PGS.pharma

- ACE and AT1 inhibitors, response to (*CYP2C9, CYP2C19, CYP2D6, CYP3A4*)
- Alcohol metabolism (*ADH1B, ALDH2*)
- Anesthetics /muscle relaxants (*BCHE, CYP2B6*)
- Antibiotics, metabolism of (*CYP3A4, NAT2*)
- Antidepressants, effect /metabolism of (*COMT, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4*)
- Antidiabetics, oral (sulphonylureas), metabolism of (*CYP2C19*)
- Beta blockers, response to (*ADRB1, ADRB2, CYP2C9, CYP2C19, CYP2D6, CYP3A4*)

- Diabetic nephropathy, risk of (*SOD2*)
- Diabetic retinopathy, risk of (*PON1*)
- Efavirenz toxicity (*CYP2B6*)
- Favism, G6PD deficiency, drug induced hemolytic anemia (*G6PD*)
- HIV protease inhibitors (indinavir, nelfinavir), metabolism of (*CYP2C19, CYP3A4*)
- HIV treatment, response to; resistance to specific HIV strains (*CCR5*)
- Ibuprofen, toxicity /metabolism of (*CYP2C9, UGT1A1*)
- Immunosuppressants (tacrolimus, cyclosporin) Treatment success /metabolism of (*ABCB1, CYP3A4, CYP3A5*)
- Irinotecan, toxicity of (*UGT1A1*)
- Isoniacid, toxicity of (*NAT2*)
- Metabolism of clopidogrel (*CYP2C19*)
- Metabolism of coumarin (*VKORC1, CYP2C9*)
- Methotrexate, treatment success /toxicity of (*SLC19A1, MTHFR*)
- Multi-drug resistance, response /bioavailability /transport of various drugs (*ABCB1*)
- NSAIDs (aspirin, diclofenac, ibuprofen), metabolism of (*CYP2C9*)
- Paracetamol, toxicity /metabolism of (*CYP2A6, UGT1A1*)
- Proton pump inhibitors (PPI), metabolism of (*CYP2C19, CYP3A4*)
- Statin treatment, intolerance /effect (*SLCO1B1, CYP2C9, CYP2D6, CYP3A4*)
- Tamoxifen, effect of (*CYP2D6*)
- Thiopurine analogs, toxicity of (*TPMT*)
- 5-fluorouracil (5-FU) toxicity (*DPD*)

PGS.androgen receptor

- Testosterone sensitivity (*AR*)

PGS.carrier

- Alpha-1 antitrypsin deficiency, chronic lung disease (*AAT*)
- Bloom’s syndrome (*BLM*)
- Canavan’s disease (*ASPA*)
- Copper storage disease (Wilsons disease) (*ATP7B*)
- Cystic fibrosis (mucoviscidosis) (*CFTR*)
- Disposition for thrombophilia (*F2, F5, MTHFR, PAI1*)
- Familial dysautonomia (*IKBKAP*)
- Familial Mediterranean fever (*MEFV*)
- Favism, G6PD deficiency (*G6PD*)
- Folic acid metabolism (*SLC19A1, MTHFR*)
- Fructose intolerance, hereditary (*ALDOB*)
- Gaucher’s disease (*GBA*)
- Gilbert’s disease (*UGT1A1*)
- Hemochromatosis (*HFE*)
- MCAD deficiency (*ACADM*)
- Mucopolipidosis (*MCOLN1*)
- Nieman-Pick disease (*SMPD1*)
- Non-syndromic hardness of hearing (*GJB2, GJB6*)
- Sickle cell disease (*HBB*)
- Tay-Sachs disease (*HEXA*)

PGS.complete

- Includes PGS.pharma, PGS.prevention, PGS.carrier